nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.0998	0.279	CbGbCtD
Bortezomib—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.0838	0.234	CbGbCtD
Bortezomib—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0696	0.195	CbGbCtD
Bortezomib—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.0637	0.178	CbGbCtD
Bortezomib—Synovial cyst—Cyclosporine—focal segmental glomerulosclerosis	0.0432	0.133	CcSEcCtD
Bortezomib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0405	0.113	CbGbCtD
Bortezomib—Gingival hypertrophy—Cyclosporine—focal segmental glomerulosclerosis	0.0179	0.0553	CcSEcCtD
Bortezomib—Progressive multifocal leukoencephalopathy—Cyclosporine—focal segmental glomerulosclerosis	0.011	0.0341	CcSEcCtD
Bortezomib—PSMD1—nephron tubule—focal segmental glomerulosclerosis	0.0104	0.0778	CbGeAlD
Bortezomib—PSMD2—nephron tubule—focal segmental glomerulosclerosis	0.00917	0.0689	CbGeAlD
Bortezomib—Posterior reversible encephalopathy syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.0091	0.0281	CcSEcCtD
Bortezomib—PSMD1—cortex of kidney—focal segmental glomerulosclerosis	0.00886	0.0666	CbGeAlD
Bortezomib—PSMD2—kidney—focal segmental glomerulosclerosis	0.00806	0.0606	CbGeAlD
Bortezomib—PSMB5—nephron tubule—focal segmental glomerulosclerosis	0.00805	0.0605	CbGeAlD
Bortezomib—PSMD2—cortex of kidney—focal segmental glomerulosclerosis	0.00785	0.059	CbGeAlD
Bortezomib—PSMB8—cortex of kidney—focal segmental glomerulosclerosis	0.0078	0.0586	CbGeAlD
Bortezomib—PSMB1—nephron tubule—focal segmental glomerulosclerosis	0.00704	0.0529	CbGeAlD
Bortezomib—PSMB5—cortex of kidney—focal segmental glomerulosclerosis	0.00689	0.0518	CbGeAlD
Bortezomib—PSMB2—nephron tubule—focal segmental glomerulosclerosis	0.00687	0.0516	CbGeAlD
Bortezomib—Autonomic neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00658	0.0203	CcSEcCtD
Bortezomib—PSMB1—kidney—focal segmental glomerulosclerosis	0.00618	0.0465	CbGeAlD
Bortezomib—PSMB2—kidney—focal segmental glomerulosclerosis	0.00603	0.0454	CbGeAlD
Bortezomib—PSMB1—cortex of kidney—focal segmental glomerulosclerosis	0.00602	0.0453	CbGeAlD
Bortezomib—SLC31A1—nephron tubule—focal segmental glomerulosclerosis	0.00595	0.0447	CbGeAlD
Bortezomib—Tonsillitis—Cyclosporine—focal segmental glomerulosclerosis	0.00591	0.0183	CcSEcCtD
Bortezomib—PSMB2—cortex of kidney—focal segmental glomerulosclerosis	0.00588	0.0442	CbGeAlD
Bortezomib—Acute respiratory distress syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00572	0.0177	CcSEcCtD
Bortezomib—SLC31A1—kidney—focal segmental glomerulosclerosis	0.00523	0.0393	CbGeAlD
Bortezomib—SLC31A1—cortex of kidney—focal segmental glomerulosclerosis	0.00509	0.0383	CbGeAlD
Bortezomib—Skin infection—Cyclosporine—focal segmental glomerulosclerosis	0.00495	0.0153	CcSEcCtD
Bortezomib—Sensation of foreign body—Cyclosporine—focal segmental glomerulosclerosis	0.00458	0.0141	CcSEcCtD
Bortezomib—Polyneuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00458	0.0141	CcSEcCtD
Bortezomib—Eye swelling—Cyclosporine—focal segmental glomerulosclerosis	0.00458	0.0141	CcSEcCtD
Bortezomib—Pigmentation disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00448	0.0138	CcSEcCtD
Bortezomib—Lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.00428	0.0132	CcSEcCtD
Bortezomib—Non-Hodgkin's lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.00428	0.0132	CcSEcCtD
Bortezomib—Paresis—Cyclosporine—focal segmental glomerulosclerosis	0.00409	0.0126	CcSEcCtD
Bortezomib—PTGS1—endothelium—focal segmental glomerulosclerosis	0.00387	0.0291	CbGeAlD
Bortezomib—Bacterial infection—Cyclosporine—focal segmental glomerulosclerosis	0.00324	0.00999	CcSEcCtD
Bortezomib—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.00324	0.00999	CcSEcCtD
Bortezomib—Thrombocytopenic purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00319	0.00983	CcSEcCtD
Bortezomib—Azotaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.00865	CcSEcCtD
Bortezomib—Ear disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00277	0.00854	CcSEcCtD
Bortezomib—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.00277	0.00854	CcSEcCtD
Bortezomib—Gingival bleeding—Cyclosporine—focal segmental glomerulosclerosis	0.00263	0.00813	CcSEcCtD
Bortezomib—Fracture—Cyclosporine—focal segmental glomerulosclerosis	0.00257	0.00793	CcSEcCtD
Bortezomib—Multiple fractures—Cyclosporine—focal segmental glomerulosclerosis	0.00257	0.00793	CcSEcCtD
Bortezomib—Urine analysis abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00254	0.00784	CcSEcCtD
Bortezomib—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.00246	0.00758	CcSEcCtD
Bortezomib—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.00238	0.00734	CcSEcCtD
Bortezomib—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.00726	CcSEcCtD
Bortezomib—Encephalopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00233	0.00718	CcSEcCtD
Bortezomib—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0023	0.00711	CcSEcCtD
Bortezomib—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.00223	0.0069	CcSEcCtD
Bortezomib—Myopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00213	0.00657	CcSEcCtD
Bortezomib—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.00211	0.00651	CcSEcCtD
Bortezomib—Tongue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.00634	CcSEcCtD
Bortezomib—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00612	CcSEcCtD
Bortezomib—Cholestasis—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00607	CcSEcCtD
Bortezomib—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.00193	0.00597	CcSEcCtD
Bortezomib—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.00193	0.00597	CcSEcCtD
Bortezomib—CYP2C8—kidney—focal segmental glomerulosclerosis	0.00192	0.0145	CbGeAlD
Bortezomib—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00592	CcSEcCtD
Bortezomib—Coagulopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00592	CcSEcCtD
Bortezomib—Rigors—Cyclosporine—focal segmental glomerulosclerosis	0.00183	0.00565	CcSEcCtD
Bortezomib—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00548	CcSEcCtD
Bortezomib—CYP1A1—kidney—focal segmental glomerulosclerosis	0.00177	0.0133	CbGeAlD
Bortezomib—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00175	0.0054	CcSEcCtD
Bortezomib—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.00532	CcSEcCtD
Bortezomib—Cardiovascular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.00525	CcSEcCtD
Bortezomib—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.00521	CcSEcCtD
Bortezomib—Viral infection—Cyclosporine—focal segmental glomerulosclerosis	0.00165	0.0051	CcSEcCtD
Bortezomib—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00507	CcSEcCtD
Bortezomib—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00507	CcSEcCtD
Bortezomib—Lacrimation increased—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.005	CcSEcCtD
Bortezomib—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.005	CcSEcCtD
Bortezomib—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00161	0.00497	CcSEcCtD
Bortezomib—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.0016	0.00494	CcSEcCtD
Bortezomib—Hearing impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00157	0.00484	CcSEcCtD
Bortezomib—PTGS1—kidney—focal segmental glomerulosclerosis	0.00156	0.0117	CbGeAlD
Bortezomib—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00152	0.0047	CcSEcCtD
Bortezomib—Hepatocellular injury—Cyclosporine—focal segmental glomerulosclerosis	0.00149	0.00461	CcSEcCtD
Bortezomib—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.00149	0.00461	CcSEcCtD
Bortezomib—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.00453	CcSEcCtD
Bortezomib—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00445	CcSEcCtD
Bortezomib—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.00143	0.0044	CcSEcCtD
Bortezomib—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.00438	CcSEcCtD
Bortezomib—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.0014	0.00433	CcSEcCtD
Bortezomib—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00421	CcSEcCtD
Bortezomib—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00421	CcSEcCtD
Bortezomib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.00417	CcSEcCtD
Bortezomib—Abnormal vision—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.00402	CcSEcCtD
Bortezomib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.0013	0.00979	CbGeAlD
Bortezomib—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.004	CcSEcCtD
Bortezomib—CYP2D6—kidney—focal segmental glomerulosclerosis	0.00128	0.00963	CbGeAlD
Bortezomib—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00392	CcSEcCtD
Bortezomib—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00385	CcSEcCtD
Bortezomib—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00122	0.00378	CcSEcCtD
Bortezomib—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00374	CcSEcCtD
Bortezomib—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00374	CcSEcCtD
Bortezomib—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00372	CcSEcCtD
Bortezomib—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00371	CcSEcCtD
Bortezomib—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.00361	CcSEcCtD
Bortezomib—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00356	CcSEcCtD
Bortezomib—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00352	CcSEcCtD
Bortezomib—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00113	0.0035	CcSEcCtD
Bortezomib—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00113	0.00347	CcSEcCtD
Bortezomib—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00344	CcSEcCtD
Bortezomib—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00343	CcSEcCtD
Bortezomib—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00342	CcSEcCtD
Bortezomib—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00335	CcSEcCtD
Bortezomib—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00332	CcSEcCtD
Bortezomib—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00329	CcSEcCtD
Bortezomib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.000994	0.00307	CcSEcCtD
Bortezomib—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00099	0.00306	CcSEcCtD
Bortezomib—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00098	0.00302	CcSEcCtD
Bortezomib—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.000977	0.00301	CcSEcCtD
Bortezomib—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00096	0.00296	CcSEcCtD
Bortezomib—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.000956	0.00295	CcSEcCtD
Bortezomib—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.000944	0.00291	CcSEcCtD
Bortezomib—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000937	0.00289	CcSEcCtD
Bortezomib—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.000922	0.00285	CcSEcCtD
Bortezomib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000919	0.00284	CcSEcCtD
Bortezomib—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.000901	0.00278	CcSEcCtD
Bortezomib—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000899	0.00277	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000871	0.00269	CcSEcCtD
Bortezomib—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.000866	0.00267	CcSEcCtD
Bortezomib—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.000853	0.00263	CcSEcCtD
Bortezomib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000848	0.00262	CcSEcCtD
Bortezomib—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000846	0.00261	CcSEcCtD
Bortezomib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000841	0.00259	CcSEcCtD
Bortezomib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000836	0.00258	CcSEcCtD
Bortezomib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000836	0.00258	CcSEcCtD
Bortezomib—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.000824	0.00254	CcSEcCtD
Bortezomib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000822	0.00254	CcSEcCtD
Bortezomib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000819	0.00253	CcSEcCtD
Bortezomib—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000819	0.00253	CcSEcCtD
Bortezomib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000815	0.00251	CcSEcCtD
Bortezomib—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000812	0.00251	CcSEcCtD
Bortezomib—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000812	0.00251	CcSEcCtD
Bortezomib—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.000797	0.00246	CcSEcCtD
Bortezomib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00079	0.00244	CcSEcCtD
Bortezomib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000788	0.00243	CcSEcCtD
Bortezomib—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000784	0.00242	CcSEcCtD
Bortezomib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000754	0.00233	CcSEcCtD
Bortezomib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00075	0.00232	CcSEcCtD
Bortezomib—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00075	0.00232	CcSEcCtD
Bortezomib—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000746	0.0023	CcSEcCtD
Bortezomib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000741	0.00229	CcSEcCtD
Bortezomib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000737	0.00228	CcSEcCtD
Bortezomib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000735	0.00227	CcSEcCtD
Bortezomib—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000723	0.00223	CcSEcCtD
Bortezomib—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000699	0.00216	CcSEcCtD
Bortezomib—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000696	0.00215	CcSEcCtD
Bortezomib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000681	0.0021	CcSEcCtD
Bortezomib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000676	0.00209	CcSEcCtD
Bortezomib—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000673	0.00208	CcSEcCtD
Bortezomib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.00067	0.00207	CcSEcCtD
Bortezomib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000657	0.00203	CcSEcCtD
Bortezomib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000653	0.00202	CcSEcCtD
Bortezomib—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000644	0.00199	CcSEcCtD
Bortezomib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00064	0.00197	CcSEcCtD
Bortezomib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000628	0.00194	CcSEcCtD
Bortezomib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000615	0.0019	CcSEcCtD
Bortezomib—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000612	0.00189	CcSEcCtD
Bortezomib—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000606	0.00187	CcSEcCtD
Bortezomib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000604	0.00186	CcSEcCtD
Bortezomib—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.0006	0.00185	CcSEcCtD
Bortezomib—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000597	0.00184	CcSEcCtD
Bortezomib—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000589	0.00182	CcSEcCtD
Bortezomib—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000587	0.00181	CcSEcCtD
Bortezomib—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000585	0.0018	CcSEcCtD
Bortezomib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00057	0.00176	CcSEcCtD
Bortezomib—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000566	0.00175	CcSEcCtD
Bortezomib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000564	0.00174	CcSEcCtD
Bortezomib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000556	0.00172	CcSEcCtD
Bortezomib—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000556	0.00172	CcSEcCtD
Bortezomib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000556	0.00172	CcSEcCtD
Bortezomib—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000554	0.00171	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000552	0.0017	CcSEcCtD
Bortezomib—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000549	0.0017	CcSEcCtD
Bortezomib—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000537	0.00166	CcSEcCtD
Bortezomib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000533	0.00164	CcSEcCtD
Bortezomib—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000533	0.00164	CcSEcCtD
Bortezomib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00053	0.00163	CcSEcCtD
Bortezomib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000523	0.00161	CcSEcCtD
Bortezomib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000522	0.00161	CcSEcCtD
Bortezomib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000518	0.0016	CcSEcCtD
Bortezomib—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000515	0.00159	CcSEcCtD
Bortezomib—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000508	0.00157	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000486	0.0015	CcSEcCtD
Bortezomib—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000482	0.00149	CcSEcCtD
Bortezomib—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000479	0.00148	CcSEcCtD
Bortezomib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000475	0.00147	CcSEcCtD
Bortezomib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000469	0.00145	CcSEcCtD
Bortezomib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000463	0.00143	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00046	0.00142	CcSEcCtD
Bortezomib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00046	0.00142	CcSEcCtD
Bortezomib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000456	0.00141	CcSEcCtD
Bortezomib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000456	0.00141	CcSEcCtD
Bortezomib—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000439	0.00136	CcSEcCtD
Bortezomib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000436	0.00135	CcSEcCtD
Bortezomib—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000423	0.00131	CcSEcCtD
Bortezomib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000421	0.0013	CcSEcCtD
Bortezomib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000421	0.0013	CcSEcCtD
Bortezomib—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000393	0.00121	CcSEcCtD
Bortezomib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000382	0.00118	CcSEcCtD
Bortezomib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000377	0.00116	CcSEcCtD
Bortezomib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000365	0.00113	CcSEcCtD
Bortezomib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000352	0.00109	CcSEcCtD
Bortezomib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000339	0.00105	CcSEcCtD
Bortezomib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000336	0.00104	CcSEcCtD
Bortezomib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000336	0.00104	CcSEcCtD
Bortezomib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000334	0.00103	CcSEcCtD
Bortezomib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000317	0.000977	CcSEcCtD
Bortezomib—PSMB8—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.000126	0.000678	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000124	0.00067	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000124	0.00067	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000124	0.00067	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000123	0.000661	CbGpPWpGaD
Bortezomib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—focal segmental glomerulosclerosis	0.000122	0.000659	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000121	0.00065	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000121	0.00065	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.00012	0.000647	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.00012	0.000647	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.00012	0.000647	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD40LG—focal segmental glomerulosclerosis	0.00012	0.000644	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.00012	0.000644	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.00012	0.000644	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000119	0.000643	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD40LG—focal segmental glomerulosclerosis	0.000119	0.000641	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000119	0.00064	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD40LG—focal segmental glomerulosclerosis	0.000118	0.000638	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000117	0.000628	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000113	0.000607	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000113	0.000607	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000113	0.000607	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000113	0.000607	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD79A—focal segmental glomerulosclerosis	0.000111	0.000599	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD79A—focal segmental glomerulosclerosis	0.000111	0.000599	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD79A—focal segmental glomerulosclerosis	0.000111	0.000599	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000111	0.000599	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD79A—focal segmental glomerulosclerosis	0.00011	0.000591	CbGpPWpGaD
Bortezomib—PSMA1—Disease—LPL—focal segmental glomerulosclerosis	0.000108	0.000584	CbGpPWpGaD
Bortezomib—PSMD1—Disease—LPL—focal segmental glomerulosclerosis	0.000108	0.000581	CbGpPWpGaD
Bortezomib—PSMD2—Disease—LPL—focal segmental glomerulosclerosis	0.000107	0.000578	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000101	0.000544	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.0001	0.000541	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	9.99e-05	0.000538	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CTGF—focal segmental glomerulosclerosis	9.92e-05	0.000535	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CTGF—focal segmental glomerulosclerosis	9.92e-05	0.000535	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CTGF—focal segmental glomerulosclerosis	9.92e-05	0.000535	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CTGF—focal segmental glomerulosclerosis	9.78e-05	0.000527	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	9.32e-05	0.000502	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	9.23e-05	0.000497	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	9.18e-05	0.000495	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.15e-05	0.000493	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.15e-05	0.000493	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.15e-05	0.000493	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.14e-05	0.000493	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.14e-05	0.000493	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.14e-05	0.000493	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	9.14e-05	0.000492	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.09e-05	0.00049	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.09e-05	0.00049	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.09e-05	0.00049	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—LPL—focal segmental glomerulosclerosis	9.08e-05	0.000489	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD40LG—focal segmental glomerulosclerosis	9.06e-05	0.000488	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD40LG—focal segmental glomerulosclerosis	9.06e-05	0.000488	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD40LG—focal segmental glomerulosclerosis	9.06e-05	0.000488	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—LPL—focal segmental glomerulosclerosis	9.03e-05	0.000487	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.02e-05	0.000486	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.01e-05	0.000486	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—LPL—focal segmental glomerulosclerosis	8.99e-05	0.000484	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	8.97e-05	0.000483	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD40LG—focal segmental glomerulosclerosis	8.94e-05	0.000481	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	8.55e-05	0.000461	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NOS2—focal segmental glomerulosclerosis	8.47e-05	0.000456	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NOS2—focal segmental glomerulosclerosis	8.43e-05	0.000454	CbGpPWpGaD
Bortezomib—PSMD2—Disease—NOS2—focal segmental glomerulosclerosis	8.39e-05	0.000452	CbGpPWpGaD
Bortezomib—PSMB5—Disease—LPL—focal segmental glomerulosclerosis	8.21e-05	0.000443	CbGpPWpGaD
Bortezomib—PSMB1—Disease—LPL—focal segmental glomerulosclerosis	8.21e-05	0.000443	CbGpPWpGaD
Bortezomib—PSMB2—Disease—LPL—focal segmental glomerulosclerosis	8.21e-05	0.000443	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	8.21e-05	0.000442	CbGpPWpGaD
Bortezomib—PSMB8—Disease—LPL—focal segmental glomerulosclerosis	8.1e-05	0.000436	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	8.08e-05	0.000435	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	7.82e-05	0.000421	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	7.79e-05	0.000419	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AGT—focal segmental glomerulosclerosis	7.77e-05	0.000418	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	7.75e-05	0.000417	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AGT—focal segmental glomerulosclerosis	7.73e-05	0.000416	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AGT—focal segmental glomerulosclerosis	7.69e-05	0.000414	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	7.68e-05	0.000414	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.65e-05	0.000412	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.65e-05	0.000412	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.65e-05	0.000412	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	7.64e-05	0.000412	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	7.63e-05	0.000411	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	7.61e-05	0.00041	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.59e-05	0.000409	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.55e-05	0.000407	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.54e-05	0.000406	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	7.53e-05	0.000405	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.52e-05	0.000405	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.19e-05	0.000387	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.15e-05	0.000385	CbGpPWpGaD
Bortezomib—PSMA1—Disease—SERPINE1—focal segmental glomerulosclerosis	7.13e-05	0.000384	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.12e-05	0.000384	CbGpPWpGaD
Bortezomib—PSMD1—Disease—SERPINE1—focal segmental glomerulosclerosis	7.1e-05	0.000382	CbGpPWpGaD
Bortezomib—PSMD2—Disease—SERPINE1—focal segmental glomerulosclerosis	7.06e-05	0.00038	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.99e-05	0.000377	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.99e-05	0.000377	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.99e-05	0.000377	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	6.96e-05	0.000375	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	6.91e-05	0.000372	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.89e-05	0.000371	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—LPL—focal segmental glomerulosclerosis	6.88e-05	0.000371	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—LPL—focal segmental glomerulosclerosis	6.88e-05	0.000371	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—LPL—focal segmental glomerulosclerosis	6.88e-05	0.000371	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—LPL—focal segmental glomerulosclerosis	6.78e-05	0.000365	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	6.72e-05	0.000362	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.49e-05	0.00035	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.46e-05	0.000348	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.43e-05	0.000347	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NOS2—focal segmental glomerulosclerosis	6.42e-05	0.000346	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NOS2—focal segmental glomerulosclerosis	6.42e-05	0.000346	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NOS2—focal segmental glomerulosclerosis	6.42e-05	0.000346	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NOS2—focal segmental glomerulosclerosis	6.33e-05	0.000341	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	6.12e-05	0.00033	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	6e-05	0.000323	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.97e-05	0.000322	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—ALB—focal segmental glomerulosclerosis	5.96e-05	0.000321	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	5.94e-05	0.00032	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.94e-05	0.00032	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—ALB—focal segmental glomerulosclerosis	5.93e-05	0.00032	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.93e-05	0.000319	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.93e-05	0.000319	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.93e-05	0.000319	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ALB—focal segmental glomerulosclerosis	5.9e-05	0.000318	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—LIPC—focal segmental glomerulosclerosis	5.89e-05	0.000318	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AGT—focal segmental glomerulosclerosis	5.89e-05	0.000317	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AGT—focal segmental glomerulosclerosis	5.89e-05	0.000317	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AGT—focal segmental glomerulosclerosis	5.89e-05	0.000317	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.84e-05	0.000315	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	5.82e-05	0.000314	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	5.82e-05	0.000314	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	5.82e-05	0.000314	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AGT—focal segmental glomerulosclerosis	5.8e-05	0.000313	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.75e-05	0.00031	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.75e-05	0.00031	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.75e-05	0.00031	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	5.74e-05	0.000309	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.69e-05	0.000307	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.67e-05	0.000306	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.45e-05	0.000294	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.45e-05	0.000294	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.45e-05	0.000294	CbGpPWpGaD
Bortezomib—PSMB5—Disease—SERPINE1—focal segmental glomerulosclerosis	5.4e-05	0.000291	CbGpPWpGaD
Bortezomib—PSMB2—Disease—SERPINE1—focal segmental glomerulosclerosis	5.4e-05	0.000291	CbGpPWpGaD
Bortezomib—PSMB1—Disease—SERPINE1—focal segmental glomerulosclerosis	5.4e-05	0.000291	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.37e-05	0.000289	CbGpPWpGaD
Bortezomib—PSMB8—Disease—SERPINE1—focal segmental glomerulosclerosis	5.33e-05	0.000287	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	5.3e-05	0.000286	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	5.23e-05	0.000282	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.22e-05	0.000281	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CTGF—focal segmental glomerulosclerosis	5.19e-05	0.00028	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.99e-05	0.000269	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.97e-05	0.000268	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.94e-05	0.000266	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.92e-05	0.000265	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.92e-05	0.000265	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.92e-05	0.000265	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.87e-05	0.000262	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.85e-05	0.000261	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.78e-05	0.000258	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	4.66e-05	0.000251	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.55e-05	0.000245	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.55e-05	0.000245	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.55e-05	0.000245	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ALB—focal segmental glomerulosclerosis	4.52e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ALB—focal segmental glomerulosclerosis	4.52e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ALB—focal segmental glomerulosclerosis	4.52e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TGFB1—focal segmental glomerulosclerosis	4.5e-05	0.000242	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.48e-05	0.000242	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TGFB1—focal segmental glomerulosclerosis	4.48e-05	0.000241	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.46e-05	0.00024	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TGFB1—focal segmental glomerulosclerosis	4.46e-05	0.00024	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ALB—focal segmental glomerulosclerosis	4.45e-05	0.00024	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	4.25e-05	0.000229	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—LIPC—focal segmental glomerulosclerosis	4.15e-05	0.000224	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.98e-05	0.000215	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.82e-05	0.000206	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	3.81e-05	0.000205	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.81e-05	0.000205	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.79e-05	0.000204	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.78e-05	0.000204	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.78e-05	0.000204	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.78e-05	0.000204	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.74e-05	0.000201	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.73e-05	0.000201	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CTGF—focal segmental glomerulosclerosis	3.66e-05	0.000197	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.63e-05	0.000196	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	3.63e-05	0.000195	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—LPL—focal segmental glomerulosclerosis	3.6e-05	0.000194	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.42e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—focal segmental glomerulosclerosis	3.41e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—focal segmental glomerulosclerosis	3.41e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—focal segmental glomerulosclerosis	3.41e-05	0.000184	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	3.4e-05	0.000183	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.37e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—focal segmental glomerulosclerosis	3.36e-05	0.000181	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	3.35e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.15e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.14e-05	0.000169	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	3.13e-05	0.000168	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.12e-05	0.000168	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.1e-05	0.000167	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	3.1e-05	0.000167	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.09e-05	0.000166	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AGT—focal segmental glomerulosclerosis	3.08e-05	0.000166	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.06e-05	0.000165	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	2.99e-05	0.000161	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.9e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.9e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.9e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.86e-05	0.000154	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.79e-05	0.00015	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.76e-05	0.000149	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	2.75e-05	0.000148	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	2.73e-05	0.000147	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	2.65e-05	0.000143	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.53e-05	0.000137	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—LPL—focal segmental glomerulosclerosis	2.53e-05	0.000137	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.51e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.39e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.39e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.39e-05	0.000129	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.38e-05	0.000128	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—focal segmental glomerulosclerosis	2.36e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.35e-05	0.000127	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	2.33e-05	0.000126	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	2.32e-05	0.000125	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AGT—focal segmental glomerulosclerosis	2.17e-05	0.000117	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.15e-05	0.000116	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	2.07e-05	0.000112	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	2.04e-05	0.00011	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	1.99e-05	0.000107	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	1.91e-05	0.000103	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	1.89e-05	0.000102	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	1.8e-05	9.69e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	1.77e-05	9.56e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—focal segmental glomerulosclerosis	1.66e-05	8.96e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.66e-05	8.93e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	1.63e-05	8.79e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	1.62e-05	8.71e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	1.62e-05	8.7e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	1.53e-05	8.22e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	1.38e-05	7.45e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	1.36e-05	7.33e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	1.25e-05	6.75e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	1.25e-05	6.72e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	1.24e-05	6.69e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	1.07e-05	5.75e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	1.06e-05	5.71e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	8.19e-06	4.41e-05	CbGpPWpGaD
